“…The results of the randomized studies, which have been completed to date involving interferon alfa based regimens, clearly indicate that interferon alfa is active in this disease. Patients who are most likely to respond and who should be offered interferon alfa therapy are those who are less than 70 years old, with good performance status, and metastases in either the lungs or the lymph nodes (17,18). Various studies have attempted to identify other possible prognostic factors, which could be used to identify patients most likely to benefit from interferon alfa based therapy (4,6,17,18).…”